| | Year | Author | PFS HR (95% CI) | CSS HR (95% CI) | OS HR (95% CI) | No. of covariates | Adjusted variables (part) |
| | 2018 | Ikeda et al. | 2.51 (1.552-4.07) | 3.5 (1.954-6.259) | NA | 11 | Age, gender, tumor location, pN, history of BC, adjuvant therapy, pT, tumor grade, CIS, tumor architecture | | 2018 | Kohada et al. | 2.65 (1.52-4.67) | 2.62 (1.06-6.96) | NA | 5 | pT, tumor grade, hydronephrosis | | 2018 | Abe et al. | 1.162 (0.647-2.133) | 2.11 (0.988-4.839) | 1.326 (0.697-2.52) | 3 | pN, pT, tumor grade | | 2018 | Kim et al. | 1.76 (1.4-2.21) | 1.9 (1.49-2.44) | 1.85 (1.48-2.31) | 14 | Age, gender, operation, tumor location, pN, history of BC, adjuvant therapy, pT, tumor grade, CIS, BMI | | 2018 | Tan et al. | 1.02 (0.73-1.43) | 1.16 (0.79-1.7) | 1.16 (0.82-1.65) | 14 | Age, gender, tumor location, pN, adjuvant therapy, pT, tumor grade, tumor architecture, multifocality | | 2018 | Kim et al. | 1.859 (1.464-2.36) | 1.829 (1.43-2.338) | 1.776 (1.36-2.32) | 8 | Tumor grade, tumor architecture, margin status, pN | | 2017 | Huang et al. | NA | 1.72 (1.14-2.59) | 1.51 (1.04-2.2) | 6 | Age, pN, pT, tumor grade, multifocality | | 2017 | Nakagawa et al. | 2.02 (0.85-5.61) | 3.02 (0.76-20.43) | NA | 5 | Age, adjuvant therapy, tumor grade, hydronephrosis | | 2017 | Cho et al. | 1.69 (1.37-2.09) | 2.78 (1.88-4.1) | 1.98 (1.42-2.77) | 19 | Age, gender, operation, tumor location, pN, history of BC, pT, CIS, hydronephrosis, multifocality, BMI | | 2016 | Tai et al. | 1.05 (0.56-1.95) | NA | NA | 3 | Tumor location, pT, tumor grade | | 2016 | Shibing et al. | 0.802 (0.6-1.072) | 0.909 (0.68-1.215) | 0.913 (0.695-1.2) | 10 | Age, operation, tumor location, pN, pT, tumor grade, tumor architecture | | 2016 | Song et al. | 3.165 (0.487-20.565) | 4.898 (0.563-42.626) | NA | 15 | Age, gender, tumor location, history of BC, pT, tumor grade, hydronephrosis | | 2016 | Kobayashi et al. | 2.02 (1.46-2.8) | 2.28 (1.55-3.36) | NA | 6 | Age, gender, pN, adjuvant therapy, pT, tumor grade | | 2016 | Waseda et al. | 2.7 (1.97-3.69) | 2.83 (1.95-4.1) | NA | 5 | Age, tumor location, pN, pT, tumor grade | | 2016 | Mbeutcha et al. | NA | 1.23 (0.83-1.81) | 1.35 (0.98-1.87) | 12 | Age, gender, tumor location, pN, history of BC, adjuvant therapy, pT, tumor grade, CIS, tumor architecture | | 2016 | Matsumoto et al. | 1.88 (0.73-5.03) | 1.32 (0.46-3.82) | 1.07 (0.44-2.61) | 6 | pT, tumor grade | | 2016 | Kim et al. | NA | 1.82 (0.99-3.32) | NA | 3 | Tumor location, history of BC, tumor grade | | 2015 | Tanaka et al. | NA | NA | 1.67 (1.01-2.74) | 4 | Age, adjuvant therapy, pT, tumor grade | | 2015 | Hara et al. | 3.19 (2.09-4.87) | NA | NA | 16 | Age, gender, operation, tumor location, pN, history of BC, adjuvant therapy, pT, tumor grade, margin status | | 2015 | Lee et al. | 1.71 (1-2.93) | 1.38 (0.69-2.75) | NA | 4 | pN, pT, tumor grade | | 2015 | Kang et al. | NA | 3.097 (1.81-5.297) | 2.4 (1.469-3.921) | 9 | Age, adjuvant therapy, pT, tumor grade, margin status, multifocality, adjuvant therapy, BMI | | 2015 | Milojevic et al. | 0.58 (0.32-1.07) | NA | NA | 5 | pN, history of BC, adjuvant therapy, pT, tumor grade | | 2014 | Aziz et al. | 2.7 (1.59-4.57) | 2.5 (1.45-4.3) | 1.91 (1.22-2.98) | 10 | Age, tumor location, pN, pT, tumor grade, tumor architecture, multifocality | | 2013 | Liu et al. | NA | 1.16 (0.818-1.645) | NA | 13 | Age, gender, operation, tumor location, pN, adjuvant therapy, pT, tumor grade, margin status, multifocality | | 2013 | Hurel et al. | 2.14 (1.38-3.3) | 1.73 (1.01-2.95) | NA | 8 | Age, tumor location, pN, adjuvant therapy, pT, tumor grade, margin status | | 2013 | Ouzzane et al. | NA | NA | 1.57 (1.03-2.4) | 6 | Age, tumor location, pN, pT, tumor grade, margin status | | 2012 | Chromecki et al. | 1.31 (1.1-1.57) | 1.41 (1.16-1.72) | NA | 10 | Age, gender, tumor location, pN, adjuvant therapy, pT, tumor grade, tumor architecture, multifocality |
|
|
